FES Antikörper (N-Term)
-
- Target Alle FES Antikörper anzeigen
- FES (Feline Sarcoma Oncogene (FES))
-
Bindungsspezifität
- N-Term
-
Reaktivität
- Human, Maus, Ratte
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser FES Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB)
- Spezifität
- FES antibody was raised against the N terminal of FES
- Aufreinigung
- Affinity purified
- Immunogen
- FES antibody was raised using the N terminal of FES corresponding to a region with amino acids ARDSAQAKRKYQEASKDKDRDKAKDKYVRSLWKLFAHHNRYVLGVRAAQL
- Top Product
- Discover our top product FES Primärantikörper
-
-
- Applikationshinweise
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. - Kommentare
-
FES Blocking Peptide, catalog no. 33R-1466, is also available for use as a blocking control in assays to test for specificity of this FES antibody
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of FES antibody in PBS
- Konzentration
- Lot specific
- Buffer
- PBS
- Handhabung
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. - Lagerung
- 4 °C/-20 °C
- Informationen zur Lagerung
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
- Target
- FES (Feline Sarcoma Oncogene (FES))
- Andere Bezeichnung
- FES (FES Produkte)
- Synonyme
- FPS antikoerper, RGD1564385 antikoerper, AI586313 antikoerper, BB137047 antikoerper, c-fes antikoerper, FES antikoerper, c-fps antikoerper, FES proto-oncogene, tyrosine kinase antikoerper, feline sarcoma oncogene antikoerper, FES antikoerper, Fes antikoerper, fes antikoerper
- Hintergrund
- FES is the human cellular counterpart of a feline sarcoma retrovirus protein with transforming capabilities. FES has tyrosine-specific protein kinase activity and that activity is required for maintenance of cellular transformation. Its chromosomal location has linked it to a specific translocation event identified in patients with acute promyelocytic leukemia but it is also involved in normal hematopoiesis.
- Molekulargewicht
- 93 kDa (MW of target protein)
- Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Signaling Events mediated by VEGFR1 and VEGFR2
-